Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, ...

In the latest close session, Moderna (MRNA) was down 1.48% at $47.99. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Elsewhere, the Dow gained 0.64%, while the ...

We learn what the findings could mean for fighting cancer ...

The head of Robert F. Kennedy Jr.’s panel of independent vaccine advisers recently questioned the necessity of the polio ...

Schizophrenia is a complex mental health disorder, but scientists are learning more about what can cause it... | Genetics And ...

Acid resistance is a crucial property that enterobacteria must possess to withstand host acidic environments during infection ...

Stock markets offered investors a deal on three companies last Friday. Intel (INTC) ran up from $35 last month to around $54, ...

A new study published in the Proceedings of the National Academy of Sciences suggests that rare cases of brain inflammation ...

The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.

By adding AI-enabled RNA design and active learning, Eclipsebio extends its sequencing-based analytics platform into a fully ...